Artificial intelligence is now making its mark in the pharmaceutical industry as well. An AI-driven drug research company has accelerated its efforts to treat a lung disease. They have initiated Phase 2 trials for an AI-powered drug for idiopathic pulmonary fibrosis (IPF).
Can AI drug treat IPF?
The AI-powered drug will be administered to 60 lung disease patients. IPF, a lung condition similar to asthma and COPD, affects millions of people worldwide, with no known cure thus far. However, Insilico Medicine has announced a significant milestone in meeting the medical needs for IPF.
AI Utilization Insilico Medicine leveraged the power of artificial intelligence to identify protein structures that could potentially treat IPF. By using AI to explore molecules that can inhibit these proteins, the company claims to have reached an “unprecedented stage” for IPF treatment.
Google's DeepMind CEO claims that their new AI model, Gemini, will outperform OpenAI's ChatGPT. Here's the detail.
The Phase 2 trials for this drug will be conducted on patients in China and the United States, with analysis performed on 60 individuals. It is worth noting that Insilico Medicine has agreements with some industry giants in the healthcare sector, such as Sanofi and Johnson & Johnson.
While the development of an AI-based drug for IPF is still underway, Insilico Medicine is also engaged in other research endeavors. They have initiated testing on 12 drugs for various diseases, including liver cancer and breast cancer, across different phases.
The Phase 2 trials for Insilico Medicine’s IPF drug represent a significant milestone in the medical sector. The second report on the drug is expected to be shared within three months.
